FDA raises concerns over efficacy of Merck's potential chronic cough drug ahead of adcomm
The FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet Friday to discuss Merck’s application for its chronic cough oral drug gefapixant, with the agency saying the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.